BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Samonakis DN, Koulentaki M, Coucoutsi C, Augoustaki A, Baritaki C, Digenakis E, Papiamonis N, Fragaki M, Matrella E, Tzardi M, Kouroumalis EA. Clinical outcomes of compensated and decompensated cirrhosis: A long term study. World J Hepatol 2014; 6(7): 504-512 [PMID: 25068002 DOI: 10.4254/wjh.v6.i7.504] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Zhao H, Wang Q, Luo C, Liu L, Xie W. Recompensation of Decompensated Hepatitis B Cirrhosis: Current Status and Challenges. Biomed Res Int 2020;2020:9609731. [PMID: 33029534 DOI: 10.1155/2020/9609731] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Thomas JN, Roopkumar J, Patel T. Machine learning analysis of volatolomic profiles in breath can identify non-invasive biomarkers of liver disease: A pilot study. PLoS One 2021;16:e0260098. [PMID: 34847181 DOI: 10.1371/journal.pone.0260098] [Reference Citation Analysis]
3 Sobotka LA, Modi RM, Vijayaraman A, Hanje AJ, Michaels AJ, Conteh LF, Hinton A, El-Hinnawi A, Mumtaz K. Paracentesis in cirrhotics is associated with increased risk of 30-day readmission. World J Hepatol 2018; 10(6): 425-432 [PMID: 29988878 DOI: 10.4254/wjh.v10.i6.425] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Nilsson E, Anderson H, Sargenti K, Lindgren S, Prytz H. Clinical course and mortality by etiology of liver cirrhosis in Sweden: a population based, long-term follow-up study of 1317 patients. Aliment Pharmacol Ther 2019;49:1421-30. [DOI: 10.1111/apt.15255] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
5 Saffo S, Garcia-Tsao G, Taddei T. SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension. J Diabetes 2021;13:265-9. [PMID: 33210815 DOI: 10.1111/1753-0407.13136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Lawitz E, Poordad F, Gutierrez JA, Beumont M, Beets G, Vandevoorde A, Remoortere PV, Luo D, Vijgen L, Eygen VV, Gamil M. Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT study. Health Sci Rep 2020;3:e145. [PMID: 32270053 DOI: 10.1002/hsr2.145] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Srivastava A, Jong S, Gola A, Gailer R, Morgan S, Sennett K, Tanwar S, Pizzo E, O'Beirne J, Tsochatzis E, Parkes J, Rosenberg W. Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease. BMC Gastroenterol 2019;19:122. [PMID: 31296161 DOI: 10.1186/s12876-019-1039-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
8 Terefe Tesfaye B, Gudina EK, Bosho DD, Mega TA. Short-term clinical outcomes of patients admitted with chronic liver disease to selected teaching hospitals in Ethiopia. PLoS One 2019;14:e0221806. [PMID: 31469861 DOI: 10.1371/journal.pone.0221806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Biewenga M, Verhelst XPDMJ, Baven-Pronk MAMC, Putter H, van den Berg AP, van Nieuwkerk KCMJ, van Buuren HR, Bouma G, de Boer YS, Simoen C, Colle I, Schouten J, Sermon F, van Steenkiste C, van Vlierberghe H, van der Meer AJ, Nevens F, van Hoek B; Dutch Autoimmune Hepatitis Study Group. Development and validation of a prognostic score for long-term transplant-free survival in autoimmune hepatitis type 1. United European Gastroenterol J 2021;9:662-71. [PMID: 34165262 DOI: 10.1002/ueg2.12112] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Abdel Moneim M, Abdelaziz DH, Ibrahim Nagy Y, Abdel Baki A, Attia AS, Sabry N. Rifaximin microbial resistance and its efficacy and safety as a secondary prophylaxis of hepatic encephalopathy in patients with hepatitis C virus-related cirrhosis. Int J Clin Pract 2021;75:e14807. [PMID: 34487412 DOI: 10.1111/ijcp.14807] [Reference Citation Analysis]
11 Chou AH, Chen CC, Lin YS, Lin MS, Wu VC, Ting PC, Chen SW. A population-based analysis of endovascular aortic stent graft therapy in patients with liver cirrhosis. J Vasc Surg 2019;69:1395-1404.e4. [PMID: 30528408 DOI: 10.1016/j.jvs.2018.06.225] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
12 Safaie P, Poongkunran M, Kuang PP, Javaid A, Jacobs C, Pohlmann R, Nasser I, Lau DT. Intrahepatic distribution of hepatitis B virus antigens in patients with and without hepatocellular carcinoma. World J Gastroenterol 2016; 22(12): 3404-3411 [PMID: 27022222 DOI: 10.3748/wjg.v22.i12.3404] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
13 Kouroumalis E, Voumvouraki A. Hepatitis C virus: A critical approach to who really needs treatment. World J Hepatol 2022; 14(1): 1-44 [DOI: 10.4254/wjh.v14.i1.1] [Reference Citation Analysis]
14 Sobotka LA, Mumtaz K, Hinton A, Kelly SG, Conteh LF, Michaels AJ, Hanje AJ, Wellner MR. Cannabis use may reduce healthcare utilization and improve hospital outcomes in patients with cirrhosis. Ann Hepatol 2021;23:100280. [PMID: 33157269 DOI: 10.1016/j.aohep.2020.10.008] [Reference Citation Analysis]
15 Samonakis DN, Gatselis N, Bellou A, Sifaki-Pistolla D, Mela M, Demetriou G, Thalassinos E, Rigopoulou EI, Kevrekidou P, Tziortziotis I, Azariadi K, Kavousanaki M, Digenakis E, Vassiliadis T, Kouroumalis EA, Dalekos GN. Spontaneous bacterial peritonitis: a prospective Greek multicenter study of its epidemiology, microbiology, and outcomes. Ann Gastroenterol 2022;35:80-7. [PMID: 34987293 DOI: 10.20524/aog.2021.0674] [Reference Citation Analysis]
16 D’amico G, Perricone G. Prediction of Decompensation in Patients with Compensated Cirrhosis: Does Etiology Matter? Curr Hepatology Rep 2019;18:144-56. [DOI: 10.1007/s11901-019-00473-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Yoon JH, Jun CH, Kim JH, Yoon EL, Kim BS, Song JE, Suk KT, Kim MY, Kang SH. Changing Trends in Liver Cirrhosis Etiology and Severity in Korea: the Increasing Impact of Alcohol. J Korean Med Sci 2021;36:e145. [PMID: 34060260 DOI: 10.3346/jkms.2021.36.e145] [Reference Citation Analysis]
18 Lesmana CRA, Raharjo M, Gani RA. Managing liver cirrhotic complications: Overview of esophageal and gastric varices. Clin Mol Hepatol 2020;26:444-60. [PMID: 33053928 DOI: 10.3350/cmh.2020.0022] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
19 Lawitz E, Poordad F, Gutierrez JA, Kakuda TN, Picchio G, Beets G, Vandevoorde A, Van Remoortere P, Jacquemyn B, Luo D, Ouwerkerk-Mahadevan S, Vijgen L, Van Eygen V, Beumont M. Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease. J Viral Hepat 2017;24:287-94. [PMID: 27878906 DOI: 10.1111/jvh.12645] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
20 Sobotka LA, Spitzer C, Hinton A, Michaels A, Hanje AJ, Mumtaz K, Conteh LF. Management of hepatic hydrothorax and effect on length of stay, mortality, cost, and 30-day hospital readmission. J Gastroenterol Hepatol 2020;35:641-7. [PMID: 31441096 DOI: 10.1111/jgh.14842] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Simon J, Ouro A, Ala-Ibanibo L, Presa N, Delgado TC, Martínez-Chantar ML. Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover. Int J Mol Sci 2019;21:E40. [PMID: 31861664 DOI: 10.3390/ijms21010040] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
22 Alkhalili E, Greenbaum A, Luo L, Rodriguez R, Caldwell K, Estrada OM, O'Neill J, Nir I, Morris KT. Viral hepatitis status does not affect survival in patients with hepatocellular carcinoma. Ann Gastroenterol 2017;30:101-5. [PMID: 28042245 DOI: 10.20524/aog.2016.0097] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
23 Kamal S, Khan MA, Seth A, Cholankeril G, Gupta D, Singh U, Kamal F, Howden CW, Stave C, Nair S, Satapathy SK, Ahmed A. Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2017;112:1495-1505. [PMID: 28585556 DOI: 10.1038/ajg.2017.170] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 10.6] [Reference Citation Analysis]
24 Abara WE, Spradling P, Zhong Y, Moorman A, Teshale EH, Rupp L, Gordon SC, Schmidt M, Boscarino JA, Daida YG, Holmberg SD; CHeCS Investigators. Hepatocellular Carcinoma Surveillance in a Cohort of Chronic Hepatitis C Virus-Infected Patients with Cirrhosis. J Gastrointest Cancer 2020;51:461-8. [PMID: 31124041 DOI: 10.1007/s12029-019-00255-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Spradley FT, Smith JA, Alexander BT, Anderson CD. Developmental origins of nonalcoholic fatty liver disease as a risk factor for exaggerated metabolic and cardiovascular-renal disease. Am J Physiol Endocrinol Metab 2018;315:E795-814. [PMID: 29509436 DOI: 10.1152/ajpendo.00394.2017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
26 Duah A, Agyei-Nkansah A, Osei-Poku F, Duah F, Addo BP. Sociodemographic characteristics, complications requiring hospital admission and causes of in-hospital death in patients with liver cirrhosis admitted at a district hospital in Ghana. PLoS One 2021;16:e0253759. [PMID: 34166471 DOI: 10.1371/journal.pone.0253759] [Reference Citation Analysis]